IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026

Reported 12-month objective response rates exceeded 90% in both the cryoablation-alone and combination-treatment groups.

Rhea-AI Summary

IceCure Medical (Nasdaq: ICCM) presented ProSense breast cancer cryoablation clinical data at the European Society of Breast Imaging’s 2026 annual meeting.

Presentations reported 12-month objective response rates, a measure of tumor response, of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation alone. Cryoablation destroys tumors by freezing. The meeting took place in Maastricht, the Netherlands.

ProSense featured in two scientific sessions, including findings on elderly breast cancer patients ineligible for surgery. IceCure hosted two clinical workshops, each attracting nearly 70 participants. Two posters by ProSense users addressed one-year outcomes for breast lesions in Romania and imaging to predict tissue response after breast cryoablation.

Positive

• Minor pointCryoablation plus endocrine therapy showed a 97.5% 12-month objective response rate among 40 patients.
• Minor pointCryoablation alone showed a 91.7% 12-month objective response rate among 24 patients.

Negative

• None.

Argus 15 min delay 4 alerts

+6.48% vs previous close $1.15 last price 57.0x rel. volume Open Argus

Details

Market move: ICCM +6.48% vs previous close. 12-month clinical data

+9.5% Peak Tracked

$1.08 – $1.27 Day Range

$5.33M Market Cap

On Oct 13, the day this news came out, the latest delayed price for ICCM is 6.48% above the previous close. Argus tracked a peak move of +9.5% during the session. Our momentum scanner has recorded 4 alerts for this stock so far that day. The latest delayed price is $1.15. Relative volume is exceptionally heavy at 57.0x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Objective response rate: 97.5% Objective response rate: 91.7%

Objective response rate

97.5%

12-month data; cryoablation plus endocrine therapy; 40 patients

Objective response rate

91.7%

12-month data; cryoablation alone; 24 patients

Key Terms

cryoablation, objective response rates, endocrine therapy, contrast enhancement mammography

4 terms

cryoablation medical

"breast cancer cryoablation was featured in multiple scientific presentations"

A medical treatment that uses extreme cold to freeze and destroy unwanted tissue, such as small tumors or heart tissue causing irregular rhythms; think of it like applying a focused freezer to stop a problem spot without cutting it out. It matters to investors because devices, tools, and drugs tied to cryoablation, plus clinical results, approval status and insurance coverage, can drive sales, shape market adoption and affect the financial outlook of healthcare companies.

objective response rates medical

"reporting objective response rates of 97.5% among 40 patients"

Objective response rate (ORR) is the share of patients in a clinical trial whose disease shows a clear, measurable improvement—usually tumor shrinkage or disappearance—based on predefined criteria. For investors, ORR offers a concrete early signal of a therapy’s effectiveness: higher ORR can increase the drug’s chance of regulatory approval, commercial value, and revenue potential, much like a product’s percent of satisfied customers predicting market success.

endocrine therapy medical

"patients treated with cryoablation plus endocrine therapy"

Endocrine therapy is a medical treatment that reduces or blocks hormones that help certain tumors grow, for example by lowering production of the hormone or preventing it from attaching to cancer cells. Think of it as cutting off the fuel supply to slow or stop growth. Investors care because these therapies drive sales, long-term treatment demand, regulatory milestones and clinical trial outcomes that directly affect healthcare companies’ revenues and valuations.

contrast enhancement mammography medical

"Negative CEM (Contrast Enhancement Mammography) in Predicting Histological Response"

A mammography technique that uses an injected iodinated contrast agent and specialized X‑ray imaging to make areas of increased blood flow in the breast more visible; images are typically acquired at different energy levels (spectral imaging) so contrast-enhanced tissue stands out against normal breast tissue. It highlights regions with abnormal vascularity—often associated with tumors—so it can reveal lesions that are hard to see on ordinary mammograms, but it requires intravenous contrast (so it is not used in patients with certain allergies or severe kidney disease) and does not replace other imaging modalities when those provide different or complementary information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Scientific presentations, research posters and clinical workshops featured ProSense^® breast cancer cryoablation and highlighted strong physician engagement across Europe

CAESAREA, Israel, October 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, announced today that ProSense^® breast cancer cryoablation was featured in multiple scientific presentations, research posters and physician workshops at the European Society of Breast Imaging ("EUSOBI") Annual Scientific Meeting 2026, held in Maastricht, the Netherlands. Featured presentations included 12-month clinical data reporting objective response rates of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation alone.

ProSense^® was featured during two key scientific sessions at EUSOBI, reflecting clinical interest in breast cancer cryoablation in Europe. Dr. Lucía Graña-López (Lugo, Spain) presented the clinical potential of cryoablation during her presentation "Beyond Biopsy: Image-Guided Therapy in Practice" during the session "From Target to Treatment: Breast Interventions." Dr. Francesca Pugliese (Florence, Italy) shared her findings from "Local Tumor Control in Elderly Breast Cancer Patients Ineligible for Surgery: Cryoablation Alone or Combined with Hormonal Therapy" during the session on "Advances in Image-Guided Breast Intervention and Minimally Invasive Therapy."

The Company also hosted two well-attended clinical workshops, led by Dr. Lucía Graña-López (Lugo, Spain) and Dr. Federica Di Naro (Florence, Italy): "From Freeze to Future: Cryoablation as a New Frontier in De-Escalated Breast Cancer Care" and "Reading the Freeze: Practical Imaging Interpretation After Breast Cancer Cryoablation". Each workshop attracted nearly 70 participants.

Two scientific posters by ProSense^® users were presented: "From Initial Experience to One-Year Outcomes: Single-Center Efficacy and Safety of Percutaneous Cryoablation for Breast Lesions in Romania" by Dr. Georgiana-Cristiana Camen (Romania) and "When Enhancement Disappears: The Role of Negative CEM (Contrast Enhancement Mammography) in Predicting Histological Response After Breast Cryoablation" by Dr. Francesca Pugliese (Florence, Italy).

EUSOBI is a leading European organization dedicated to breast imaging and education, bringing together breast radiologists and other specialists from across Europe and internationally. The Annual Scientific Meeting provides a platform for the exchange of clinical knowledge, research and advances in breast imaging and treatment.

"We are thrilled by the tremendous enthusiasm and engagement ProSense^® generated throughout EUSOBI," said Eyal Shamir, Chief Executive Officer of IceCure Medical. "From live demonstrations and two key scientific sessions to two workshops attended by nearly 70 participants each, the response was outstanding. The inclusion of ProSense^® in scientific posters and the presentation of encouraging 12-month clinical results further demonstrate the growing momentum behind breast cancer cryoablation and the expanding role of ProSense^® in advancing minimally invasive care across Europe."

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, as a safe and effective minimally invasive option to surgical tumor removal, with the primary focus areas being breast, kidney, bone and lung cancer. The Company's flagship ProSense^® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.

ProSense^® cryoablation became the first-and-only medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery.

Investor Relations:

Meir Peleg, CFO

investors@icecure-medical.com 

+1-888-902-5716

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. For example, the Company is using forward-looking statements when it discusses: the potential for increased physician interest in, adoption of, and use of ProSense^® and breast cancer cryoablation, including in Europe; the potential of expansion of ProSense^®'s role in minimally invasive breast cancer care; and the potential for broader commercial adoption of ProSense^®. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/icecure-highlights-clinical-data-and-strong-physician-engagement-for-prosense-breast-cancer-cryoablation-at-eusobi-2026-302906818.html

SOURCE IceCure Medical

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What clinical results did IceCure report for ProSense at EUSOBI 2026?

The presentations reported 12-month objective response rates of 97.5% among 40 patients receiving cryoablation plus endocrine therapy and 91.7% among 24 patients receiving cryoablation alone. Cryoablation is a treatment that destroys tumors by freezing.